Liminatus Pharma Receives Nasdaq Delisting Notice for Sub-$1 Bid Price

summarizeSummary

Liminatus Pharma received a Nasdaq delisting notice for failing to maintain a minimum $1 bid price, initiating a 180-day compliance period to avoid potential delisting.

check_boxKey Events · Corporate Governance and Compliance · LIMN

• Nasdaq Delisting Notice Received

  On January 15, 2026, Liminatus Pharma, Inc. received a notice from Nasdaq indicating non-compliance with the minimum $1 bid price rule (Rule 5450(a)(1)) for the last 30 consecutive business days.

• 180-Day Compliance Period

  The company has been granted a 180-calendar-day period, until July 14, 2026, to regain compliance by maintaining a closing bid price of at least $1 for a minimum of ten consecutive business days.

• Potential Reverse Stock Split

  To regain compliance, the company may consider implementing a reverse stock split, which must be completed no later than ten business days prior to the compliance period's expiration.

• No Immediate Effect on Listing

  The notification does not have an immediate impact on the listing of the company's common stock, which will continue to trade on Nasdaq under the symbol 'LIMN'.

auto_awesomeAnalysis · LIMN · Life Sciences

Liminatus Pharma, a micro-cap company, has received a critical notice from Nasdaq regarding its failure to maintain the minimum $1 bid price requirement. This is a significant event as continued non-compliance could lead to the delisting of its common stock, severely impacting liquidity and investor confidence. The company has 180 days to regain compliance, which often necessitates a reverse stock split, a move that can be dilutive and negatively perceived by the market. Investors should monitor the company's actions to address this deficiency, as failure to comply poses a substantial risk to the stock's trading viability on Nasdaq.